Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 96Rectal Neoplasms 45Colorectal Neoplasms 45Carcinoma, Non-Small-Cell Lung 31Esophageal Neoplasms 28Esophageal Squamous Cell Carcinoma 24Stomach Neoplasms 22Lung Neoplasms 20Pancreatic Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Colonic Neoplasms 18Neoplasms 16Sarcoma 15Adenocarcinoma Of Esophagus 15Ovarian Neoplasms 14Neoplasm Metastasis 14Head and Neck Neoplasms 14Carcinoma, Hepatocellular 14Prostatic Neoplasms 13Urinary Bladder Neoplasms 12Uterine Cervical Neoplasms 10Inflammatory Breast Neoplasms 9Fallopian Tube Neoplasms 9Osteosarcoma 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Carcinoma, Ovarian Epithelial 7Recurrence 6Multiple Myeloma 6

Interventions

Nivolumab 3Cisplatin 2Albumin-Bound Paclitaxel 2tislelizumab 1spartalizumab 1Taxes 1Standard of Care 1Radiotherapy 1Neoadjuvant Therapy 1Immunotherapy 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle-Invasive Bladder Carcinoma × Neoadjuvant Therapy × Clear all
NCT06325423 2024-03-26

Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer

Assiut University

Not yet recruiting
50 enrolled

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡